

Castration Resistant Prostate Cancer Treatment Market 2026

<https://marketpublishers.com/r/CCA24F2A5794EN.html>

Date: November 2025

Pages: 217

Price: US\$ 2,999.00 (Single User License)

ID: CCA24F2A5794EN

Abstracts

The Castration Resistant Prostate Cancer Treatment Market was valued at in and is anticipated to reach by , at a CAGR of 0.09 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Castration Resistant Prostate Cancer Treatment Market.

This report delivers a comprehensive overview of the Castration Resistant Prostate Cancer Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Castration Resistant Prostate Cancer Treatment Market. The Castration Resistant Prostate Cancer Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for –.

Castration Resistant Prostate Cancer Treatment Market Scope:

By Treatment

Chemotherapy

Hormonal therapy

Targeted therapy

Surgery

Others

By End-users

Hospitals

Specialty Clinics

Diagnostic laboratory

Others

Key Players

Bayer Healthcare Pharmaceuticals

Active Biotech AB

Diagnocure

GlaxoSmithKline PLC

Northwest Biotherapeutics

Millennium Pharmaceuticals

Hologic

Spectrum Pharmaceuticals

Abbott Laboratories(LIST NOT EXHAUSTIVE)

Major Highlights

This report delivers a comprehensive overview of the Castration Resistant Prostate Cancer Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Castration Resistant Prostate Cancer Treatment Market. The Castration Resistant Prostate Cancer Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for –.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned

to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

2. MARKET DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

- 3.1. Market Snippet by Treatment
- 3.2. Market Snippet by End-users
- 3.3. Market Snippet by Region

4. MARKET DYNAMICS

4.1. Market Impacting Factors

4.1.1. Drivers

4.1.1.1. Emerging novel therapies for the treatment of castration-resistant prostate cancer are expected to drive market growth.

4.1.2. Restraints:

4.1.2.1. Side Effects associated with hormone therapy for the treatment of castration-resistant prostate cancer are expected to hamper the market's growth.

4.1.3. Opportunity

4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

- 5.1. Porter's Five Forces Analysis
- 5.2. Epidemiology Analysis
- 5.3. Supply Chain Analysis
- 5.4. Pricing Analysis
- 5.5. Unmet Needs

6. COVID-19 ANALYSIS

- 6.1. Analysis of Covid-19 on the Market
 - 6.1.1. Before COVID-19 Market Scenario

- 6.1.2. Present COVID-19 Market Scenario
- 6.1.3. After COVID-19 or Future Scenario
- 6.2. Pricing Dynamics Amid Covid-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During Pandemic
- 6.5. Manufacturers Strategic Initiatives
- 6.6. Conclusion

7. BY TREATMENT

- 7.1. Introduction
 - 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
 - 7.1.2. Market Attractiveness Index, By Treatment Segment
- 7.2. Chemotherapy*
 - 7.2.1. Docetaxel (Taxotere)
 - 7.2.2. Others
 - 7.2.3. Introduction
 - 7.2.4. Market Size Analysis, US\$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
- 7.3. Hormonal therapy
 - 7.3.1. Apalutamide
 - 7.3.2. Darolutamide
 - 7.3.3. Enzalutamide
 - 7.3.4. Others
- 7.4. Targeted therapy
 - 7.4.1. Olaparib (Lynparza)
 - 7.4.2. Rucaparib (Rubraca)
 - 7.4.3. Others
- 7.5. Surgery
- 7.6. Others

8. BY END-USERS

- 8.1. Introduction
 - 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
 - 8.1.2. Market Attractiveness Index, By End-users Segment
- 8.2. Hospitals*
 - 8.2.1. Introduction
 - 8.2.2. Market Size Analysis, US\$ Million, 2019-2028 and Y-o-Y Growth Analysis (%),

2020-2028

8.3. Specialty Clinics

8.4. Diagnostic laboratory

8.5. Others

9. BY REGION

9.1. Introduction

9.1.1. Market Size Analysis, US\$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region

9.1.2. Market Attractiveness Index, By Region

9.2. North America

9.2.1. Introduction

9.2.2. Key Region-Specific Dynamics

9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment

9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users

9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

9.2.5.1. U.S.

9.2.5.2. Canada

9.2.5.3. Mexico

9.3. Europe

9.3.1. Introduction

9.3.2. Key Region-Specific Dynamics

9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment

9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users

9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

9.3.5.1. Germany

9.3.5.2. U.K.

9.3.5.3. France

9.3.5.4. Italy

9.3.5.5. Spain

9.3.5.6. Rest of Europe

9.4. South America

9.4.1. Introduction

9.4.2. Key Region-Specific Dynamics

9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment

9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users

9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

9.4.5.1. Brazil

9.4.5.2. Argentina

9.4.5.3. Rest of South America

9.5. Asia Pacific

9.5.1. Introduction

9.5.2. Key Region-Specific Dynamics

9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment

9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users

9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

9.5.5.1. China

9.5.5.2. India

9.5.5.3. Japan

9.5.5.4. Australia

9.5.5.5. Rest of Asia Pacific

9.6. Middle East and Africa

9.6.1. Introduction

9.6.2. Key Region-Specific Dynamics

9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment

9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users

10. COMPETITIVE LANDSCAPE

10.1. Key Developments and Strategies

10.2. Company Share Analysis

10.3. Product Benchmarking

10.4. List of Key Companies to Watch

10.5. List of Company with disruptive technology

10.6. List of Start-Up Companies

11. COMPANY PROFILES

11.1. Bayer Healthcare Pharmaceuticals*

11.1.1. Company Overview

11.1.2. Product Portfolio and Description

11.1.3. Key Highlights

11.1.4. Financial Overview

11.2. Active Biotech AB

11.3. Diagnocure

11.4. GlaxoSmithKline PLC

11.5. Northwest Biotherapeutics

11.6. Millennium Pharmaceuticals

11.7. Hologic

11.8. Spectrum Pharmaceuticals

11.9. Abbott Laboratories(*LIST NOT EXHAUSTIVE)

12. DATAM INTELLIGENCE

12.1. Appendix

12.2. About Us

12.3. Contact Us

I would like to order

Product name: Castration Resistant Prostate Cancer Treatment Market 2026

Product link: <https://marketpublishers.com/r/CCA24F2A5794EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CCA24F2A5794EN.html>